Is Grail Stock a Bad-News Buy After Its Recent Pullback?

Grail's stock dropped from a record high of $116 in January to $68 after its NHS trial for the Galleri cancer blood test failed to meet its primary endpoint in February. Despite the setback, the company continues strong direct sales (56,000+ tests in Q1) and expects 22-32% revenue growth this year. The stock trades at 15x sales and could benefit from eventual FDA approval, making it a speculative but potentially worthwhile investment for long-term investors.